1.12

10.89% 0.11

Coherus Biosciences Inc (CHRS)

Overview News Price History Option Chain Financials Why CHRS Down? Discussions Forecast

Coherus Biosciences Inc stock is traded at $1.12, with a volume of 2.97M. It is up +10.89% in the last 24 hours and up +22.31% over the past month. Coherus BioSciences Inc is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer. Coherus is developing an innovative immuno-oncology pipeline which includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and enhance outcomes for patients with cancer.

Previous Close:

$1.01

Open:

$1.02

24h Volume:

2.97M

Relative Volume:

1.52

Market Cap:

$112.95M

Revenue:

$257.24M

Net Income/Loss:

$-237.89M

P/E Ratio:

-0.4308

EPS:

-2.6

Net Cash Flow:

$-175.17M

1W Performance:

+50.90%

1M Performance:

+22.31%

6M Performance:

+32.04%

1Y Performance:

-47.91%

1-Day Range:

$1.01

$1.14

1-Week Range:

$0.75

$1.14

52-Week Range:

$0.6603

$2.43

Coherus Biosciences Inc Stock (CHRS) Company Profile

Name

Coherus Biosciences Inc

Sector

Healthcare (1151)

Industry

Biotechnology (660)

Phone

(650) 649-3530

Address

C/O DENNIS M. LANFEAR, REDWOOD CITY, CA

Employee

228

Twitter

@coherus_bio

Next Earnings Date

2025-03-10

Latest SEC Filings

CHRS's Discussions on Twitter

Compare CHRS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CHRS Coherus Biosciences Inc	1.12	112.95M	257.24M	-237.89M	-175.17M	-2.60
VRTX Vertex Pharmaceuticals Inc	489.10	127.47B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	563.16	62.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	596.20	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	234.56	31.06B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	230.98	26.16B	3.81B	-644.79M	-669.77M	-6.24

Coherus Biosciences Inc Stock (CHRS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-16-24	Downgrade	UBS	Buy → Neutral
Nov-17-23	Initiated	Robert W. Baird	Outperform
Nov-08-23	Downgrade	Maxim Group	Buy → Hold
Jul-24-23	Initiated	Citigroup	Buy
May-01-23	Initiated	Truist	Buy
Mar-28-23	Upgrade	UBS	Neutral → Buy
Jun-14-22	Initiated	UBS	Neutral
Mar-07-22	Downgrade	JP Morgan	Overweight → Neutral
Jul-16-20	Initiated	BofA Securities	Neutral
Apr-17-20	Initiated	SunTrust	Buy
Aug-13-19	Initiated	Mizuho	Buy
Aug-02-19	Reiterated	H.C. Wainwright	Buy
Aug-02-19	Reiterated	Maxim Group	Buy
Jun-11-19	Initiated	Barclays	Overweight
May-07-19	Initiated	H.C. Wainwright	Buy
Aug-28-18	Initiated	H.C. Wainwright	Buy
Mar-09-18	Reiterated	Maxim Group	Buy
Aug-08-17	Reiterated	JP Morgan	Overweight
Jun-13-17	Reiterated	Maxim Group	Buy
May-05-17	Initiated	BMO Capital Markets	Outperform
Oct-19-16	Initiated	Robert W. Baird	Outperform
Sep-07-16	Initiated	Maxim Group	Buy
Jul-27-16	Initiated	Citigroup	Buy
Jan-20-16	Initiated	Credit Suisse	Outperform

View All

Coherus Biosciences Inc Stock (CHRS) Latest News

Apr 17, 2025

Coherus BioSciences: Cleaning The Balance Sheet And Developing New Drugs - Seeking Alpha

Apr 17, 2025

Apr 16, 2025

Coherus Marks Exit From Biosimilars By Completing Udenyca Divestment - insights.citeline.com

Apr 16, 2025

Apr 15, 2025

Coherus divests Udenyca franchise to Intas for up to $558.4m - MSN

Apr 15, 2025

Latham & Watkins Assists Coherus BioSciences in Obtaining CFIUS Clearance - Latham & Watkins LLP

Apr 15, 2025

Third Harmonic's shutdown, Coherus and Xoma drug sales connectedBizwomen - The Business Journals

Apr 15, 2025

Intas acquires Neulasta biosimilar Udenyca from Coherus BioSciences - World Pharmaceutical Frontiers

Apr 15, 2025

Big moves by small biotechs signal potential shift for investorsSan Francisco Business Times - The Business Journals

Apr 15, 2025

Apr 14, 2025

Coherus BioSciences (CHRS) Completes Divestiture of UDENYCA Fran - GuruFocus

Apr 14, 2025

Coherus BioSciences Completes Sale of Udenyca Franchise to Intas Pharmaceuticals for Up to $558.4 Million - marketscreener.com

Apr 14, 2025

Coherus completes strategic transformation - The Pharma Letter

Apr 14, 2025

Accord Biopharma Announces Completion Of Udenyca(Pegfilgrastim-Cbqv) Franchise Acquisition From Coherus Biosciences, Inc., Expanding U.S. Biosimilar Portfolio - marketscreener.com

Apr 14, 2025

Intas Pharmaceuticals Acquires UDENYCA Business from Coherus BioSciences - Contract Pharma

Apr 14, 2025

Accord BioPharma, Inc. Announces Completion of UDENYCA® (pegfilgrastim-cbqv) Franchise Acquisition from Coherus BioSciences, Inc., Expanding U.S. Biosimilar Portfolio - PR Newswire

Apr 14, 2025

Coherus Biosciences Completes UDENYCA Franchise Divestiture - TipRanks

Apr 14, 2025

Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise - GlobeNewswire

Apr 14, 2025

Coherus Lands Massive $558M Deal: Strategic Pivot to Oncology Extends Cash Runway to 2027 - Stock Titan

Apr 14, 2025

Apr 01, 2025

Coherus BioSciences to Repurchase $170 Million Convertible Notes - MarketScreener

Apr 01, 2025

Coherus BioSciences to repurchase $170 million in convertible notes - Investing.com India

Apr 01, 2025

Coherus BioSciences To Buy Back $170 Mln Of 1.500% Convertible Sr. Subordinated Notes - Nasdaq

Apr 01, 2025

Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes - Bluefield Daily Telegraph

Apr 01, 2025

Coherus Unveils Massive $230M Debt Reduction Plan, Starting With $170M Note Buyback - Stock Titan

Apr 01, 2025

Mar 28, 2025

Lacklustre Performance Is Driving Coherus BioSciences, Inc.'s (NASDAQ:CHRS) 27% Price Drop - simplywall.st

Mar 28, 2025

Mar 27, 2025

Coherus BioSciences : Block Advisors by H&R Block to Provide Timely Support for The Home Depot’s Pro Xtra Loyalty Members - MarketScreener

Mar 27, 2025

Mar 25, 2025

Coherus to Present Data from a Phase 1 Dose Expansion Study - GlobeNewswire

Mar 25, 2025

Breakthrough Cancer Treatment Data: Coherus' CCR8 Antibody Shows Promise in Head & Neck Cancer Trial - Stock Titan

Mar 25, 2025

Checkpoint inhibitor journey traces Chinese firms’ path to global revenue - BioWorld MedTech

Mar 25, 2025

Mar 24, 2025

Lobbying Update: $65,000 of COHERUS BIOSCIENCES INC. lobbying was just disclosed - Nasdaq

Mar 24, 2025

Shareholders Shouldn’t Be Too Comfortable With Coherus BioSciences' (NASDAQ:CHRS) Strong Earnings - simplywall.st

Mar 24, 2025

Statutory Earnings May Not Be The Best Way To Understand Coherus BioSciences' (NASDAQ:CHRS) True Position - Yahoo Finance

Mar 24, 2025

Mar 17, 2025

Coherus BioSciences, Inc. SEC 10-K Report - TradingView

Mar 17, 2025

Mar 14, 2025

Coherus BioSciences Full Year 2024 Earnings: Beats Expectations - Yahoo Finance

Mar 14, 2025

Mar 13, 2025

Coherus BioSciences Shareholders Approve UDENYCA Franchise Sale By Investing.com - Investing.com Australia

Mar 13, 2025

Coherus Prepares To Wave Goodbye To Udenyca – And 30% Of Its Staff - insights.citeline.com

Mar 13, 2025

Coherus BioSciences Shareholders Approve UDENYCA Franchise Sale - Investing.com India

Mar 13, 2025

Mar 12, 2025